Can Augmentin (amoxicillin/clavulanate) be used to treat cellulitis and urinary tract infections (UTIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Augmentin Cover for Cellulitis and UTI?

Yes, Augmentin (amoxicillin-clavulanate) is an appropriate antibiotic for both cellulitis and urinary tract infections, as it is explicitly recommended in major guidelines for both conditions.

Cellulitis Coverage

Augmentin is specifically listed as a suitable oral antibiotic for typical cellulitis cases. 1

  • The IDSA guidelines recommend antibiotics active against streptococci for typical cellulitis, and explicitly name amoxicillin-clavulanate as one of the appropriate choices alongside penicillin, amoxicillin, dicloxacillin, cephalexin, or clindamycin 1
  • For uncomplicated cellulitis, a 5-day course is as effective as a 10-day course if clinical improvement has occurred by 5 days 1
  • MRSA coverage is usually unnecessary for typical cellulitis, as β-lactams like cefazolin or oxacillin were successful in 96% of patients in prospective studies 1

When to Consider Additional MRSA Coverage

You should add MRSA coverage (and potentially avoid Augmentin monotherapy) in these specific scenarios:

  • Cellulitis associated with penetrating trauma, especially from illicit drug use 1
  • Presence of purulent drainage 1
  • Concurrent evidence of MRSA infection elsewhere 1
  • Nasal colonization with MRSA 1

UTI Coverage

Augmentin is FDA-approved for urinary tract infections caused by beta-lactamase-producing E. coli, Klebsiella species, and Enterobacter species. 2

Uncomplicated UTI

  • Augmentin can be used for uncomplicated cystitis, though it is not typically a first-line agent 3
  • First-line agents remain fosfomycin, nitrofurantoin, and pivmecillinam per European Association of Urology guidelines 3
  • Clinical trials demonstrate cure rates of approximately 70% for amoxicillin-resistant organisms when treated with Augmentin 4

Complicated UTI and Pyelonephritis

  • For complicated UTIs with systemic symptoms, Augmentin is not the preferred agent 5
  • Guidelines recommend second-generation cephalosporins plus an aminoglycoside, or third-generation cephalosporins (ceftriaxone 1-2g daily or cefotaxime 2g three times daily) for complicated UTIs 5
  • Clinical trial data show Augmentin 875/125 mg every 12 hours produced comparable bacteriological success rates to the every-8-hour regimen in pyelonephritis and complicated UTIs 2
  • Treatment duration for complicated UTIs should be 7-14 days depending on clinical response 5

Recurrent UTI

  • For recurrent UTIs, Augmentin 250/125 mg every 8 hours for 7 days achieved 84% microbiological cure rates at 1 week post-treatment and 67% at 1 month 6

Dosing Recommendations

For cellulitis: Standard adult dosing is 875/125 mg twice daily or 500/125 mg three times daily for 5 days 1, 2

For UTI:

  • Uncomplicated: 875/125 mg twice daily 2
  • Complicated: 875/125 mg twice daily for 7-14 days 2

Important Caveats

  • Always obtain urine culture before starting antibiotics for complicated UTIs due to high likelihood of resistance 5
  • Augmentin should not be used when susceptibility testing shows the organism is susceptible to amoxicillin alone (indicating no beta-lactamase production) 2
  • The drug is well-tolerated, though diarrhea occurs in approximately 15% of patients 2
  • For pyelonephritis in infants and young children, cephalexin (and by extension, likely Augmentin) is not recommended due to inadequate therapeutic bloodstream concentrations 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cephalexin Use in Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Urinary Tract Infections in Cervical Cancer Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.